Inhibition of neutrophil activation by nonsteroidal anti-inflammatory drugs.
Nonsteroidal anti-inflammatory drugs are thought to prevent inflammation in rheumatoid arthritis by inhibiting prostaglandin synthesis. This observation does not explain, however, why nonsteroidal anti-inflammatory drugs are able to control inflammation caused by other mediators. To determine whether nonsteroidal anti-inflammatory drugs also exert an effect on neutrophil activation, in vitro and in vivo studies were undertaken. Aggregation, superoxide anion generation, and lysosomal enzyme release were assessed. The nonsteroidal anti-inflammatory drugs were found to inhibit these neutrophil responses, but the patterns of inhibition varied from drug to drug. These findings suggest that nonsteroidal anti-inflammatory drugs may have direct effects on neutrophil activation that are independent of their shared inhibition of prostaglandin synthesis.
D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001241:Aspirin / Q000627:therapeutic use; D002449:Cell Aggregation / Q000187:drug effects; D006801:Humans; D007052:Ibuprofen / Q000627:therapeutic use; D066298:In Vitro Techniques; D007213:Indomethacin / Q000627:therapeutic use; D009113:Muramidase / Q000378:metabolism; D009240:N-Formylmethionine Leucyl-Phenylalanine / Q000494:pharmacology; D009504:Neutrophils / Q000187:drug effects* / Q000378:metabolism; D010894:Piroxicam; D011448:Prostaglandin Antagonists / Q000627:therapeutic use; D013481:Superoxides / Q000096:biosynthesis; D013843:Thiazines / Q000627:therapeutic use
D000893:Anti-Inflammatory Agents; D011448:Prostaglandin Antagonists; D013843:Thiazines; D013481:Superoxides; D010894:Piroxicam; D009240:N-Formylmethionine Leucyl-Phenylalanine; D009113:Muramidase; D001241:Aspirin; D007052:Ibuprofen; D007213:Indomethacin